Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Comment by Paparico1on Mar 22, 2021 12:06pm
180 Views
Post# 32850502

RE:RE:Short vol low...

RE:RE:Short vol low...
"The key point of listing on the Nasdaq was to get exposure into the market that derive most of their revenue. I would assume this is so the price per share would go up so if need they could do a PP for more acquistions of distribution agreements."

MDP has no US analyst, so when they get on the Nasdaq will not be an easy start. Everybody thinks it's a given but it isn't. The revenue increases and hopefully more/better EBIT/EBITDA will be an helpful path.

The next Fibonacci from here is 9.03 and 13.08 and that's an nice jump from here.
This company doesn't need any luck but need to keep up the consistency.
<< Previous
Bullboard Posts
Next >>